These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23322195)

  • 1. A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
    Harvey RD; Owonikoko TK; Lewis CM; Akintayo A; Chen Z; Tighiouart M; Ramalingam SS; Fanucchi MP; Nadella P; Rogatko A; Shin DM; El-Rayes B; Khuri FR; Kauh JS
    Br J Cancer; 2013 Mar; 108(4):762-5. PubMed ID: 23322195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
    Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
    Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.
    Mehnert JM; Tan AR; Moss R; Poplin E; Stein MN; Sovak M; Levinson K; Lin H; Kane M; Gounder M; Lin Y; Shih WJ; White E; Rubin EH; Karantza V
    Mol Cancer Ther; 2011 Aug; 10(8):1509-19. PubMed ID: 21680752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
    Leong S; Eckhardt SG; Chan E; Messersmith WA; Spratlin J; Camidge DR; Diab S; Khosravan R; Lin X; Chow Maneval E; Lockhart AC
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):65-74. PubMed ID: 22623210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
    Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
    Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
    Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
    Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL
    Cancer Chemother Pharmacol; 2010 May; 66(1):151-8. PubMed ID: 19774377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
    Blais N; Camidge DR; Jonker DJ; Soulières D; Laurie SA; Diab SG; Ruiz-Garcia A; Thall A; Zhang K; Chao RC; Chow LQ
    Invest New Drugs; 2013 Dec; 31(6):1487-98. PubMed ID: 23963796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
    San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
    J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
    Lieu C; Chow L; Pierson AS; Eckhardt SG; O'Bryant CL; Morrow M; Tran ZV; Wright JJ; Gore L
    Invest New Drugs; 2009 Feb; 27(1):53-62. PubMed ID: 18618082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
    Holkova B; Perkins EB; Ramakrishnan V; Tombes MB; Shrader E; Talreja N; Wellons MD; Hogan KT; Roodman GD; Coppola D; Kang L; Dawson J; Stuart RK; Peer C; Figg WD; Kolla S; Doyle A; Wright J; Sullivan DM; Roberts JD; Grant S
    Clin Cancer Res; 2011 May; 17(10):3388-97. PubMed ID: 21447728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
    Heath EI; Blumenschein GR; Cohen RB; Lorusso PM; Loconte NK; Kim ST; Ruiz-Garcia A; Chao RC; Wilding G
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):703-12. PubMed ID: 21140147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
    Michaelson MD; Zhu AX; Ryan DP; McDermott DF; Shapiro GI; Tye L; Chen I; Stephenson P; Patyna S; Ruiz-Garcia A; Schwarzberg AB
    Br J Cancer; 2013 Apr; 108(7):1393-401. PubMed ID: 23511559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
    LoConte NK; Thomas JP; Alberti D; Heideman J; Binger K; Marnocha R; Utecht K; Geiger P; Eickhoff J; Wilding G; Kolesar J
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):109-15. PubMed ID: 18322686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
    Dees EC; O'Neil BH; Lindley CM; Collichio F; Carey LA; Collins J; Riordan WJ; Ivanova A; Esseltine D; Orlowski RZ
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):99-107. PubMed ID: 18327587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
    Schelman WR; Traynor AM; Holen KD; Kolesar JM; Attia S; Hoang T; Eickhoff J; Jiang Z; Alberti D; Marnocha R; Reid JM; Ames MM; McGovern RM; Espinoza-Delgado I; Wright JJ; Wilding G; Bailey HH
    Invest New Drugs; 2013 Dec; 31(6):1539-46. PubMed ID: 24114121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.
    Schenk E; Hendrickson AE; Northfelt D; Toft DO; Ames MM; Menefee M; Satele D; Qin R; Erlichman C
    Invest New Drugs; 2013 Oct; 31(5):1251-6. PubMed ID: 23543109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
    Rini BI; Stein M; Shannon P; Eddy S; Tyler A; Stephenson JJ; Catlett L; Huang B; Healey D; Gordon M
    Cancer; 2011 Feb; 117(4):758-67. PubMed ID: 20922784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
    Holkova B; Kmieciak M; Perkins EB; Bose P; Baz RC; Roodman GD; Stuart RK; Ramakrishnan V; Wan W; Peer CJ; Dawson J; Kang L; Honeycutt C; Tombes MB; Shrader E; Weir-Wiggins C; Wellons M; Sankala H; Hogan KT; Colevas AD; Doyle LA; Figg WD; Coppola D; Roberts JD; Sullivan D; Grant S
    Clin Cancer Res; 2014 Nov; 20(22):5652-62. PubMed ID: 25248382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.